A Phase 1 interventional study of Guselkumab and Placebo in Adenomatous Polyposis Coli, sponsored by Janssen Research & Development, LLC. Completed at 32 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-03.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Adenomatous Polyposis Coli with a site in United States — 12 open to participants now, 12 under way, 1 of them phase 3. Adenomatous Polyposis Coli · United States.
Among the 39 studies in Adenomatous Polyposis Coli with a site in United States, this one is the 9th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2018, is one of 6 in phase 1, and was the 23rd registered.
92 studies on the registry are indexed under Adenomatous Polyposis Coli; 28 are open to participants now.
Browse Adenomatous Polyposis Coli studies →12 of the 39 studies in Adenomatous Polyposis Coli with a site in United States are open now. Recruiting first, the newest first:
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
HonorHealth Research Institute · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Rapamycin Holdings Inc. · Sites in United States, Denmark, Germany and 4 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Adenomatous Polyposis Coli studies recruiting now, 15 (75%) set no upper age limit and 2 (10%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 3
First in 2001; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 77 is above the median of 40 across 61 interventional studies indexed under Adenomatous Polyposis Coli.
Median enrollment 42 across the 27 interventional studies, 833 across the 12 observational. Of the 26 that completed or were terminated, 13 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
Johnson & Johnson has 3 studies filed under Adenomatous Polyposis Coli — fewer than ten, so there is no comparison to draw.
6 of the studies in Adenomatous Polyposis Coli with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04678011Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy | 2026-11 |
| NCT04677998Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis | 2026-11 |
| NCT05919264Parabilis Medicines, Inc.FOG-001 in Locally Advanced or Metastatic Solid Tumors | 2027-04-01 |
| NCT05552755Recursion Pharmaceuticals Inc.Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) | 2027-06 |
| NCT06557733National Cancer Institute (NCI)An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 39 studies in Adenomatous Polyposis Coli with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the effect of treatment with guselkumab in participants with familial adenomatous polyposis (FAP) on rectal/pouch polyp burden.
Familial adenomatous polyposis (FAP) is the most common polyposis syndrome. It is autosomal dominant inherited disorder characterized by early onset of hundreds to thousands of adenomatous polyps throughout colon. If left untreated, this syndrome may develop colorectal cancer (CRC). Polyps from individuals with FAP display inflammatory features associated with activation of interleukin (IL) 23/IL 17/JAK/STAT3 pathway. This inflammation is thought to contribute to further mutagenesis, culminating in tumor development. Specifically, IL-23 is linked to tumor growth and progression in CRC. Guselkumab is a human immunoglobulin monoclonal antibody directed against p19 subunit of IL-23, specifically targets IL-23 and inhibits its interaction with IL-23 receptor, inhibiting IL 23 specific intracellular signaling and subsequent cell activation and cytokine production, which result in less inflammation and reduce tumor development. The clinical hypothesis of this study is that treatment with guselkumab will reduce rectal/pouch polyp burden compared with baseline in active arms compared with placebo. The study is designed to determine if guselkumab has clinical activity in colorectum and duodenum, by reducing number of polyps over a period of 24 weeks. Participants will be randomized to 1 of 3 treatment arms (Guselkumab 100 mg [milligram] SC [subcutaneous], Guselkumab 300 mg SC, and placebo SC). Efficacy evaluations include rectal/pouch polyp burden assessment, biomarker analysis include discrete IL-23 signaling effector proteins (IL-23R, pSTAT3, Il-17A) and safety evaluations will include monitoring of adverse events, laboratory tests, vital sign measurements, and physical examination. Safety will be monitored throughout study (up to Week 60).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive guselkumab Dose 1 subcutaneous (SC), 6 doses every 4 weeks from Week 0 to Week 20. Participants who respond to guselkumab may continue treatment at the same dose level through Week 48.
Drug: Guselkumab
Participants will receive guselkumab Dose 2 SC, 6 doses every 4 weeks from Week 0 to Week 20. Participants who respond to guselkumab may continue treatment at the same dose level through Week 48.
Drug: Guselkumab
Participants will receive placebo SC, 6 doses every 4 weeks from Week 0 to Week 20.
Drug: Placebo
Guselkumab SC will be administered every 4 weeks.
Also known as: Tremfya
Placebo SC will be administered every 4 weeks.
Percentage Change from Baseline in Rectal/pouch Polyp Burden at Week 24
Percentage change from baseline in rectal/pouch polyp burden (sum of the polyp diameters) at Week 24 will be determined through endoscopy.
Time frame: Baseline, Week 24
Percentage Change from Baseline in Number of Colorectal Polyps
Percentage change from baseline in number of colorectal polyps will be determined.
Time frame: Baseline, Weeks 24 and 52
Percentage Change from Baseline in Number of J-pouch Polyps
Percentage change from baseline in number of J-pouch polyps will be determined.
Time frame: Baseline, Weeks 24 and 52
Percentage Change from Baseline in J-pouch Polyp Burden
Percentage change from baseline in J-pouch polyp burden (sum of polyp diameters) will be determined.
Time frame: Baseline, Weeks 24 and 52
Percentage Change from Baseline in Number of Duodenal Polyps
Percentage change from baseline in number of duodenal polyps will be determined.
Time frame: Baseline, Weeks 24 and 52
Percentage Change from Baseline in Duodenal Polyp Burden
Percentage change from baseline in duodenal polyp burden (sum of polyp diameters) will be determined.
Time frame: Baseline, Weeks 24 and 52
Change in International Society for Gastrointestinal Hereditary Tumors (InSiGHT) Stage
Change in InSiGHT stage will be determined. Various stages of InSiGHT staging system are defined as: Stage 0: 0-10 polyps, all less than (\<)5 millimeter (mm); Stage 1: 10-25 polyps, most \< 5 mm, none greater than (\>) 1 centimeter (cm); Stage 2: 10-25 polyps, any \> 1 cm, amenable to complete removal; Stage 3: \> 25 polyps amenable to complete removal, or any incompletely removed sessile polyp, or any evidence of High-Grade Dysplasia (HGD), even if completely excised; and Stage 4: \> 25 polyps amenable to complete removal, or any incompletely excised sessile polyp showing HGD, any invasive cancer).
Time frame: Baseline, Weeks 24 and 52
Change in Spigelman Stage Score
Change in Spigelman stage score will be determined. Spigelman classification system measures risk of developing duodenal cancer in familial adenomatous polyposis (FAP). It has been classified in following stages- Stage 0 (0 points); Stage 1 (1-4 points); Stage 2 (5-6 points); Stage 3 (7-8 points); and Stage 4 (9-12 points). The total score ranges from 0 to 12. Points are accumulated for polyps' number, size, histology and severity of dysplasia. Stage 1 indicates mild disease, whereas stage 3-4 indicates severe duodenal polyposis.
Time frame: Baseline, Weeks 24 and 52
Trough Concentration of Guselkumab
Serum samples will be analyzed to determine trough concentrations of guselkumab using a validated specific, and sensitive method.
Time frame: Weeks 0, 4, 8, 12, 16, 20, 24, 32, 40, and 48
Number of Participants with Anti-guselkumab Antibodies
Number of participants with Anti-guselkumab antibodies will be determined.
Time frame: Weeks 0, 4, 8, 12, 16, 20, 24, 32, 40, and 48
Anti-guselkumab Antibodies Serum Titers
Serum samples will be screened for antibodies binding to guselkumab and the titer of confirmed positive samples will be reported.
Time frame: Weeks 0, 4, 8, 12, 16, 20, 24, 32, 40, and 48
Number of Participants with Adverse Events as a Measure of Safety
An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Time frame: From Screening up to 60 Weeks
Number of Participants with Vital Sign Abnormalities as a Measure of Safety and Tolerability
Number of participants with vital sign abnormalities will be reported. Vital signs includes temperature, pulse/heart rate, respiratory rate and blood pressure.
Time frame: From Screening up to 52 Weeks
Number of Participants with Clinical Laboratory Abnormalities as a Measure of Safety and Tolerability
Number of participants with clinical laboratory abnormalities will be reported. Blood samples for serum chemistry and hematology will be collected at predefined time points for clinical laboratory testing.
Time frame: From Screening up to 52 Weeks
Relative Changes to Baseline in Levels of Interleukin (IL)-23 Effector Proteins in Biopsy Tissue
Relative Changes to Baseline in levels of IL-23 effector proteins in biopsy tissue will be measured.
Time frame: Baseline, Weeks 12, 24, and 52
Ran from Nov 2018 to primary completion in Sep 2021, 33 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guselkumab
Janssen Research & Development, LLC →